logo
Plus   Neg
Share
Email

Roche Launches Elecsys Anti-p53 Immunoassay To Diagnose Several Prevalent Cancers

Roche (RHHBY) announced the launch of the Elecsys Anti-p53 immunoassay for the in vitro quantitative determination of anti-p53 antibodies. The test is used to aid physicians to diagnose throat cancer, bowel cancer and breast cancer in patients.

Roche said the new Elecsys Anti-p53 immunoassay uses the electrochemiluminescence immunoassay ECLIA technology and is intended for use on cobas e immunoassay analyzers. It is a high precision immunoassay, with a low turn-around time for testing.

The Elecsys Anti-p53 immunoassay is now available for all markets accepting the CE Mark.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Performance Food Group Co. announced Tuesday its agreement to acquire Core-Mark Holding Co., Inc., a wholesale distributor to the convenience retail industry, in around $2.5 billion stock and cash transaction, including net debt. In pre-markey activity on Nasdaq, Core-Mark shares were gaining around 9 percent to trade at $45.86. Retail giant Walmart Inc. reported Tuesday a profit for the first quarter of fiscal 2022 that declined 31.6 percent from last year, hurt by net losses on equity investments, However, adjusted earnings per share and quarterly revenues topped analysts' expectations. The retailer also raised its guidance for the second quarter and for the full-year 2022. European Medicines Agency or EMA announced that Comirnaty, the COVID-19 vaccine developed by Pfizer and BioNTech, can have more flexible storage conditions, including up to one month in a normal fridge. The proposed change in the approved storage conditions, recommended by EMA's human medicines committee or CHMP, will help in easy handling of the vaccine in vaccination centres across the EU.
Follow RTT